GRACEcast Kidney Cancer Video

Current clinical trials are examining the possibility of giving kidney cancer (also called renal cell carcinoma, or RCC) patients immunotherapy as their first option of care upon diagnosis.

The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).

Immunotherapy Forum Video #22: Drs. Lauren Harshman and Sumanta (Monty) Pal answer questions from the audience following their presentations on immunotherapy for kidney cancer. Moderated by Dr. Marianne Davies.

Immunotherapy Forum Video #21: Dr. Sumanta (Monty) Pal reviews the past, present, and future of immunotherapy for kidney cancer and expresses concern about early study results of newer treatments. 

Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines. 

Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.

Biomarkers can give clues to many predictive and prognostic issues, like how a patient may respond to a drug or if a patient's cancer is likely to recur. Dr. Daniel Heng discusses what researchers are learning.

Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.

Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.

Dr. Daniel Heng has advice to kidney cancer patients who want the best treatment for their disease. To find a clinical trial that is right for you, visit clinicaltrials.gov and enter "kidney cancer" in the search box.

Predictive biomarkers can indicate if a patient will respond to a particular therapy. Dr. Lauren Harshman discusses if researchers know of any biomarkers for kidney cancer patients taking PD1 inhibitor drugs.

What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.

NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.

Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.

Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.

Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.

Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.

Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.

Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.

Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the main types of kidney cancer and discusses the differences in their management

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the role of surgery in the treatment of metastatic kidney cancer.

Dr. Sumanta (Monty) Pal reviews the current role of chemotherapy in the treatment of kidney cancer.

Dr. Sumanta (Monty) Pal reviews the questions on the role of surgery and what type of surgery to pursue for early stage kidney cancer.

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to first line treatment of metastatic kidney cancer.

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center discusses the current role of interleukin-2 (IL-2) in the context of many other treatment alternatives for metastatic renal cell carcinoma.

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA describes optimal management of kidney cancer that is confined to the kidney, including surgery and the role of any additional post-surgical treatment. 

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA reviews a recommended approach to the workup of a kidney mass suspected to be a cancer.